Risk-based assessment of endotoxin contamination in intravenous drug manufacturing pipelines

Endotoxin contamination presents a critical risk in intravenous (IV) drug manufacturing due to its potent pyrogenic effects and potential to cause severe patient reactions. Traditional detection methods, such as the Limulus Amebocyte Lysate (LAL) assay, provide essential safeguards but often lack the proactive insight necessary to address contamination risks across complex manufacturing pipelines. A risk-based framework is increasingly recognized as essential for identifying, quantifying, and mitigating endotoxin sources at various stages of sterile drug production. This study develops and validates a comprehensive risk-based assessment model for endotoxin contamination across upstream, formulation, and fill-finish operations in IV drug manufacturing. The framework integrates process hazard analysis (PHA), microbial control mapping, equipment exposure scoring, and historical environmental monitoring data to rank critical control points (CCPs) by endotoxin risk. Analytical techniques, including LAL assay, recombinant Factor C (rFC) assay, and high-resolution endotoxin mass spectrometry, were used to quantify endotoxin levels at key processing stages. Results indicate that water-for-injection (WFI) storage systems, aseptic filtration assemblies, and container-closure systems are among the most vulnerable CCPs, particularly when exposed to temperature fluctuations or biofilm-prone conditions. The risk model also supports prioritization of mitigation strategies, including validated cleaning-in-place (CIP) cycles, real-time endotoxin monitoring sensors, and the redesign of dead-leg-free piping systems. Implementation of this risk-based framework aligns with current regulatory expectations under ICH Q9 (Quality Risk Management) and facilitates improved contamination control strategies. By identifying systemic vulnerabilities rather than isolated failures, manufacturers can achieve more robust assurance of endotoxin-free intravenous drug products and enhanced patient safety.